Invivyd, Inc. (NASDAQ:IVVD) Short Interest Update

Invivyd, Inc. (NASDAQ:IVVD) saw a large increase in short interest in the month of January. As of January 31st, there was short interest totalling 6,620,000 shares, an increase of 5.2% from the January 15th total of 6,290,000 shares. Currently, 8.8% of the company’s shares are sold short. Based on an average daily volume of 12,710,000 shares, the days-to-cover ratio is presently 0.5 days.

Insiders Place Their Bets

In related news, Director Terrance Mcguire sold 150,000 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $0.61, for a total value of $91,500.00. Following the completion of the sale, the director now directly owns 4,538,079 shares in the company, valued at approximately $2,768,228.19. This represents a 3.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 816,466 shares of company stock valued at $423,214 in the last quarter. 17.90% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. State Street Corp boosted its stake in Invivyd by 3.7% in the 3rd quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after purchasing an additional 35,904 shares during the period. Barclays PLC boosted its stake in shares of Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after buying an additional 75,780 shares during the period. Proficio Capital Partners LLC acquired a new stake in shares of Invivyd during the 3rd quarter valued at $27,000. Two Sigma Investments LP boosted its stake in shares of Invivyd by 125.3% during the 4th quarter. Two Sigma Investments LP now owns 367,100 shares of the company’s stock valued at $163,000 after buying an additional 204,188 shares during the period. Finally, Jane Street Group LLC boosted its stake in shares of Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after buying an additional 87,358 shares during the period. Institutional investors and hedge funds own 70.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on IVVD shares. Morgan Stanley lowered their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Monday, February 3rd. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Invivyd in a research note on Tuesday, February 4th. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Invivyd has an average rating of “Buy” and an average target price of $7.89.

Invivyd Stock Performance

Invivyd stock opened at $1.61 on Tuesday. The firm has a market cap of $192.58 million, a price-to-earnings ratio of -0.82 and a beta of 0.61. Invivyd has a 1 year low of $0.35 and a 1 year high of $4.74. The firm’s 50 day moving average price is $0.72 and its two-hundred day moving average price is $0.85.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.